anoro ellipta umeclidinium vilanterol serious side effect

Umeclidinium belongs to a class of drugs called anticholinergics. Because of this, it becomes easier to breathe. It helps to relax and open the air passages in the lungs. Vilanterol belongs to a class of drugs called long-acting beta-agonists. The study was a 24-week, blinded, parallel group, multicenter study to assess the efficacy and safety of UMEC/VI 62.5/25mcg inhalation powder administered once-daily in the dry powder inhaler, Ellipta, compared to tiotropium 18mcg administered once-daily in the HandiHaler inhaler. It helps to control Wheezing, Shortness of breath, coughing and chest tightness. We hope the publication will inform physicians as they consider which treatment option is best to meet their individual patient’s needs.” These results support the lung function benefit of Anoro Ellipta in the treatment of appropriate patients with COPD. Other side effects not listed may also occur in some patients.

If you experience a serious side effect, you or your healthcare provider may send a report to the FDA's MedWatch Adverse Event Reporting Program or by phone (80).

Call your healthcare provider if you have any unusual problems while taking this medication. The incidence of any on-treatment serious adverse event in both treatment arms was 4%.ĭarrell Baker, SVP and Head, Global Respiratory Franchise, GSK said: “We are pleased to announce the publication of these important data comparing Anoro Ellipta with tiotropium. redness, pain, swelling of the eye, eyelid, or inner lining of the eyelid. Anoro Ellipta may cause other side effects. The overall incidence of on-treatment adverse events was 44% in the UMEC/VI group and 42% in the tiotropium group. The most commonly reported side effects for both UMEC/VI and tiotropium included headache (9% UMEC/VI 7% tiotropium), nasopharyngitis (6% UMEC/VI 7% tiotropium), cough (3% UMEC/VI 3% tiotropium) and back pain (2% UMEC/VI 3% tiotropium). In this study UMEC/VI 62.5/25 mcg showed a statistically significant improvement of 112mL compared with tiotropium 18mcg (95% confidence interval (CI) 81, 144, p<0.001) for the primary endpoint measurement of lung function using trough forced expiratory volume in one second (FEV1) at the end of the treatment period (day 169).įor the secondary endpoint measurement of lung function using weighted mean FEV1 0-6 hour, at the end of the treatment period (day 168) UMEC/VI 62.5/25mcg showed a statistically significant improvement of 105mL, (95% confidence interval (CI) 71, 140, p<0.001) compared to tiotropium 18 mcg. Respiratory Medicine has published positive results from a third lung function study comparing the efficacy and safety of Anoro Ellipta (umeclidinium /vilanterol, ‘UMEC/VI’), the combination long-acting muscarinic antagonist (LAMA) / long-acting beta2-adrenergic agonist (LABA), with the LAMA tiotropium, administered in the HandiHaler inhaler, in patients with COPD.

Anoro ellipta umeclidinium vilanterol serious side effect